AVAC and Access Bridge today issued a global call to action urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three ...
Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded ...
This Financial Times webinar, hosted in partnership with ViiV Healthcare, will bring together policymakers, funders, researchers, philanthropies and industry leaders to explore how to keep medical ...
AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: ...
In July, Merck announced licensing agreements with seven manufacturers for generic production of its HIV drug alimatravir, though access and equity concerns remain. As AVAC’s Executive Director ...
Seventeen countries are hosting sites for the Phase III efficacy trials of a monthly PrEP pill, called MK-8527, now known as alimatravir, being developed by Merck (also known as MSD outside of the US ...
The term autonomous means that a person can make his or her own decisions about what to do and what to agree to. Researchers must respect that individuals should make their own informed decisions ...
The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be ...
A first-in-class once-weekly oral combination of islatravir plus lenacapavir achieved viral suppression as effectively as daily oral antiretroviral therapy (ART) at week 48 in the ISLEND trial, ...
New York City, June 20, 2024 – AVAC welcomes the groundbreaking results of the PURPOSE 1 HIV prevention study among adolescent girls and young women in South Africa and Uganda. Preliminary safety and ...
The Civil Society Caucus of the Coalition to Accelerate Access to Long-Acting HIV PrEP developed a new resource that offers practical guidance to help civil society, advocates and implementers ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results